About
Douglas Lind joined Burrill & Company as a Managing Director in the Venture Group in January 2012. Previously he served as Managing Director at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Mye
Position in the VCSift Database
- • 6 investors at Biomark Capital are tracked.
- • 1,801 investors hold the Managing Director role in VCSift. Douglas Lind is one of them.
- • 190 investors are based in Greenwich, Connecticut, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Greenwich, US
Contact Information
Find more investors like Douglas
Search Investors